NEW YORK--(BUSINESS WIRE)--Dec. 14, 2005--Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, outlined recent clinical and strategic business milestones, including clinical progress on its lead anti-cancer drug candidates, in an investor conference call held Dec. 12. Company officers also answered investor questions, and discussed other achievements with respect to the growth of Callisto’s intellectual property portfolio and other key strategic efforts.
